Doxitinib mesylate

甲磺酸哆希替尼

Report date: 2026/01/27 15:06:28
NME

Base Information

Drug NameDoxitinib mesylate
Drug Alias NameDosimertinib哆希替尼Dositinib mesylate90-1408
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Deuterated drugs
Mechanisms of ActionEGFR T790M inhibitors
TargetsEGFR T790M
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHenan Genuine Biotech Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHenan Meitaibao Biopharmaceutical Co LtdHenan Normal UniversityHenan Genuine Biotech Co Ltd
Inactive CompaniesZhengzhou University
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A